It was announced today that Bionical Emas, a global Contract Research Organisation (CRO) providing a range of services to the pharmaceutical and Biotech sector, is to establish a storage, distribution, and secondary labelling facility in Ireland. Bionical Emas will be initially creating some 35 new local jobs.
Bionical Emas say that due to rapidly increasing demand for its services in the EU, US and Asia-Pacific, the facility will provide a major expansion to the existing logistics and storage capabilities. The state-of-the-art temperature-controlled (ambient and cold chain) facility will be used to store, distribute, and label medicinal products for use around the world.
It is expected that following the completion of the build-out of the facility, Bionical Emas will continue to expand its operations and Ireland based headcount across its three services areas: Clinical Development, Early Access Programs and Clinical Trial Supply.
Welcoming the news, Minister of State at the Department of Enterprise, Trade & Employment, Robert Troy said, "I am delighted that Bionical Emas has announced plans to establish a European Storage, Distribution and Labelling facility in Kilbeggan. This new state-of-the-art facility will create 35 new jobs in Westmeath, with the potential for further expansion in the years to come. This is a very welcome announcement for Kilbeggan and the wider Midlands region and demonstrates the Midlands has the skills, talent, people and connectivity that will enable companies like Bionical Emas to embed and grow their operations here."
CEO of Bionical Emas, Jonathan Waring-Hughes added, "We are extremely pleased to have chosen Kilbeggan as our new European hub - Ireland provides a great location for further expansion. Our selection of the Midlands region creates a unique opportunity to tap into the local life science talent and infrastructure. The addition of this state-of-the-art facility will further enhance our global service offerings and enable us to deliver a unique, seamless approach to bring life-changing medicines to patients around the world."